Germany, Sept. 22 -- Evonik has launched MaxiPure(R) Polysorbate 80 - a highly pure surfactant designed for injectable and biopharmaceutical applications. Engineered to meet the stringent demands of modern drug development, this ultra-high purity excipient addresses key challenges such as protein stability, viral inactivation, and the consistent solubilization of hydrophobic active pharmaceutical ingredients (APIs). With the launch of MaxiPure(R) Polysorbate 80, Evonik is expanding its support for the biopharmaceutical industry by delivering high-quality, reliable excipients that meet the growing demand for new biologics and biosimilars. Polysorbate 80 is a widely used non-ionic surfactant in pharmaceutical and biopharmaceutical formulation...